Immuron suspends research on COVID-19 program

Aug. 19, 2022 6:33 AM ETImmuron Limited (IMRN)By: Ravikash, SA News Editor

Science Laboratory


  • Immuron (NASDAQ:IMRN) said it has deprioritized SARS-CoV-2 research to focus on clinical development of its more advanced stage therapeutic drug candidates.
  • The Australian company added that it dedicated significant resources to investigate the mechanism of novel coronavirus protection, however, the

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.